Welcome to European Myeloma Network (EMN)

Participating centers

Clinical trials

News & Events

About EMN

Multiple myeloma is a rare and highly heterogeneous hematologic malignancy, and the clinical research certainly plays a fundamental role in the management of patients with this disease. To deal with such a complex scenario, in 2005, a group of European hematologists pulled together to increase their understanding of multiple myeloma and to produce effective research projects and clinical trials. These efforts resulted in the creation of the European Myeloma Network (EMN), a non profit organization. The bylaw was updated in 2017, and since 2019 the senior EMN board is composed of renowned experts in the hematologic field: Pieter Sonneveld from the Netherlands (President), Mario Boccadoro from Italy (Vice), Jesus Fernando San Miguel Izquierdo from Spain (Member),  Herman Cristoph Einsele from Germany (Member), Meletios Athanasios Dimopoulos from Greece (Member), Heinz Ludwig from Austria (Member), Philippe Moreau from France (Member), Roman Hajek from Czech Republic (Member), Annette Vangsted from Denmark (Member) and Gordon Cook from the United Kingdom (Member).